KALA

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Kala Pharmaceuticals Inc

NASDAQ | KALA

1.10

USD

$0.00

(

0.00%

)

At Close (As of Dec 2, 2025)

$10.92M

Market Cap

-

P/E Ratio

-5.64

EPS

$20.60

52 Week High

$0.60

52 Week Low

HEALTHCARE

Sector

KALA Chart

Recent Chart
Price Action

KALA Technicals

Tags:

KALA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$259K
Total Revenue $0
Cost Of Revenue $259K
Costof Goods And Services Sold $259K
Operating Income -$41M
Selling General And Administrative $18M
Research And Development $22M
Operating Expenses $40M
Investment Income Net -
Net Interest Income -$3.7M
Interest Income $2.1M
Interest Expense $5.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.3M
Income Before Tax -$39M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$39M
Comprehensive Income Net Of Tax -
Ebit -$44M
Ebitda -$41M
Net Income -$39M

Revenue & Profitability

Earnings Performance

KALA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $55M
Total Current Assets $53M
Cash And Cash Equivalents At Carrying Value $51M
Cash And Short Term Investments $51M
Inventory -
Current Net Receivables -
Total Non Current Assets $2.7M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $1.6M
Other Non Current Assets -
Total Liabilities $43M
Total Current Liabilities $17M
Current Accounts Payable $628K
Deferred Revenue -
Current Debt -
Short Term Debt $11M
Total Non Current Liabilities $26M
Capital Lease Obligations $1.8M
Long Term Debt $20M
Current Long Term Debt $10M
Long Term Debt Noncurrent -
Short Long Term Debt Total $32M
Other Current Liabilities $5M
Other Non Current Liabilities $4.7M
Total Shareholder Equity $12M
Treasury Stock -
Retained Earnings -$668M
Common Stock $6K
Common Stock Shares Outstanding $5.5M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$29M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $259K
Capital Expenditures $208K
Change In Receivables -
Change In Inventory $0
Profit Loss -
Cashflow From Investment -$208K
Cashflow From Financing $30M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$39M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$259K
Total Revenue $0
Cost Of Revenue $259K
Costof Goods And Services Sold $259K
Operating Income -$41M
Selling General And Administrative $18M
Research And Development $22M
Operating Expenses $40M
Investment Income Net -
Net Interest Income -$3.7M
Interest Income $2.1M
Interest Expense $5.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.3M
Income Before Tax -$39M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$39M
Comprehensive Income Net Of Tax -
Ebit -$44M
Ebitda -$41M
Net Income -$39M

KALA News

KALA Profile

Kala Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Kala Pharmaceuticals Inc, headquartered in Watertown, Massachusetts, is a pioneering biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced therapies for ocular conditions. Utilizing its proprietary nanoparticle-based mucus penetrating particle (MPP) technology, Kala enhances drug delivery and therapeutic outcomes in ophthalmic treatment. With a clear focus on addressing significant unmet medical needs in eye care, the company is well-positioned to lead innovation in the ophthalmology market, underscoring its commitment to transforming patient outcomes.

LPTX
+368.57%
$2.05
PAVS
-29.35%
$0.05
BYND
-3.73%
$1.29
NVDA
+0.85%
$181.46
INTC
+8.64%
$43.47
PLRZ
+131.96%
$7.33
VHAI
0.00%
$0.00
FTEL
-0.83%
$1.19
PLUG
+9.89%
$2.11
CMND
-9.93%
$0.12
TWOH
0.00%
$0.00
BITF
-5.48%
$3.10
ONDS
+6.46%
$8.07
IREN
-15.19%
$41.12
IPG
-1.95%
$24.57
TSLA
-0.20%
$429.24
AXDX
-61.36%
$0.03
AAL
+2.00%
$14.24
ASST
-1.42%
$1.03
BMNR
+10.26%
$31.91
SOFI
+1.65%
$29.51
JSPR
-8.13%
$1.58
F
-1.51%
$12.96
BBD
+1.38%
$3.67
AAPL
+1.09%
$286.19
ADAP
-15.14%
$0.05
WBD
+2.76%
$24.53
MARA
+3.38%
$11.91
BAC
-0.09%
$53.19
AMZN
+0.23%
$234.42
ACHR
+2.54%
$7.65
DNN
+2.77%
$2.59
PFE
-0.47%
$25.15
NIO
-2.89%
$5.03
SOND
-23.45%
$0.12
BMNU
+19.54%
$7.34
AMD
-2.05%
$215.24
CAN
+2.04%
$0.96
YGMZ
-21.06%
$0.08
CLSK
-2.62%
$13.71
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ABEV
+0.38%
$2.58
BTBT
-0.44%
$2.24
MRVL
+1.96%
$92.89
ADD
-25.47%
$0.05
IVP
-0.62%
$0.12
ITUB
+2.64%
$7.89
CIFR
-10.41%
$17.64
GOOGL
+0.29%
$315.81
PLTR
+1.91%
$170.69
BTG
-3.26%
$4.43
SRM
+53.27%
$10.30
RIVN
+0.40%
$17.23
GRAB
-0.18%
$5.26
APLD
-0.56%
$28.05
EXK
-1.70%
$9.24
INHD
-15.40%
$0.14
WULF
-7.05%
$14.22
BQ
+41.53%
$2.76
MSTR
+5.78%
$181.33
PLTD
-1.83%
$6.96
KVUE
-2.09%
$16.86
T
-1.04%
$25.52
SGMO
+3.47%
$0.44
VALE
+1.57%
$12.89
EB
+78.62%
$4.43
HBAN
+0.12%
$16.56
RGTI
+1.83%
$23.88
BURU
-0.76%
$0.21
WLGS
-5.57%
$0.04
ASBP
+1.11%
$0.09
SNAP
-0.26%
$7.62
MTSR
-0.35%
$70.50
RIG
-0.91%
$4.31
NFLX
+0.20%
$109.35
CRWV
-1.33%
$76.03
PCG
-3.28%
$15.32
HOOD
+2.19%
$125.95
IXHL
+12.12%
$0.39
GOOG
+0.28%
$316.02
CHR
-0.91%
$0.04
GPUS
+6.45%
$0.28
VICI
-0.48%
$28.45
AFMD
-34.94%
$0.18
VZ
-0.31%
$40.61
TMC
+17.74%
$7.40
BA
+10.14%
$205.38
AG
+2.51%
$15.91
AVGO
-1.16%
$381.57
SOUN
-2.60%
$11.22
RIOT
-1.67%
$15.22
STLA
+2.81%
$10.95
DRCT
-15.28%
$0.10
VCIG
+0.95%
$1.06
HL
+2.45%
$17.52
XYZ
-6.58%
$60.11
NOK
+1.14%
$6.19
LUMN
+10.25%
$9.14
KO
-1.77%
$70.67
LPTX
+368.57%
$2.05
PAVS
-29.35%
$0.05
BYND
-3.73%
$1.29
NVDA
+0.85%
$181.46
INTC
+8.64%
$43.47
PLRZ
+131.96%
$7.33
VHAI
0.00%
$0.00
FTEL
-0.83%
$1.19
PLUG
+9.89%
$2.11
CMND
-9.93%
$0.12
TWOH
0.00%
$0.00
BITF
-5.48%
$3.10
ONDS
+6.46%
$8.07
IREN
-15.19%
$41.12
IPG
-1.95%
$24.57
TSLA
-0.20%
$429.24
AXDX
-61.36%
$0.03
AAL
+2.00%
$14.24
ASST
-1.42%
$1.03
BMNR
+10.26%
$31.91
SOFI
+1.65%
$29.51
JSPR
-8.13%
$1.58
F
-1.51%
$12.96
BBD
+1.38%
$3.67
AAPL
+1.09%
$286.19
ADAP
-15.14%
$0.05
WBD
+2.76%
$24.53
MARA
+3.38%
$11.91
BAC
-0.09%
$53.19
AMZN
+0.23%
$234.42
ACHR
+2.54%
$7.65
DNN
+2.77%
$2.59
PFE
-0.47%
$25.15
NIO
-2.89%
$5.03
SOND
-23.45%
$0.12
BMNU
+19.54%
$7.34
AMD
-2.05%
$215.24
CAN
+2.04%
$0.96
YGMZ
-21.06%
$0.08
CLSK
-2.62%
$13.71
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ABEV
+0.38%
$2.58
BTBT
-0.44%
$2.24
MRVL
+1.96%
$92.89
ADD
-25.47%
$0.05
IVP
-0.62%
$0.12
ITUB
+2.64%
$7.89
CIFR
-10.41%
$17.64
GOOGL
+0.29%
$315.81
PLTR
+1.91%
$170.69
BTG
-3.26%
$4.43
SRM
+53.27%
$10.30
RIVN
+0.40%
$17.23
GRAB
-0.18%
$5.26
APLD
-0.56%
$28.05
EXK
-1.70%
$9.24
INHD
-15.40%
$0.14
WULF
-7.05%
$14.22
BQ
+41.53%
$2.76
MSTR
+5.78%
$181.33
PLTD
-1.83%
$6.96
KVUE
-2.09%
$16.86
T
-1.04%
$25.52
SGMO
+3.47%
$0.44
VALE
+1.57%
$12.89
EB
+78.62%
$4.43
HBAN
+0.12%
$16.56
RGTI
+1.83%
$23.88
BURU
-0.76%
$0.21
WLGS
-5.57%
$0.04
ASBP
+1.11%
$0.09
SNAP
-0.26%
$7.62
MTSR
-0.35%
$70.50
RIG
-0.91%
$4.31
NFLX
+0.20%
$109.35
CRWV
-1.33%
$76.03
PCG
-3.28%
$15.32
HOOD
+2.19%
$125.95
IXHL
+12.12%
$0.39
GOOG
+0.28%
$316.02
CHR
-0.91%
$0.04
GPUS
+6.45%
$0.28
VICI
-0.48%
$28.45
AFMD
-34.94%
$0.18
VZ
-0.31%
$40.61
TMC
+17.74%
$7.40
BA
+10.14%
$205.38
AG
+2.51%
$15.91
AVGO
-1.16%
$381.57
SOUN
-2.60%
$11.22
RIOT
-1.67%
$15.22
STLA
+2.81%
$10.95
DRCT
-15.28%
$0.10
VCIG
+0.95%
$1.06
HL
+2.45%
$17.52
XYZ
-6.58%
$60.11
NOK
+1.14%
$6.19
LUMN
+10.25%
$9.14
KO
-1.77%
$70.67
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.